Daniel Barasa, research analyst at investment firm Gabelli Funds, said it was somewhat surprising that Pfizer chose an internal candidate for the role ‘given recent activist pressure looking for fresh perspectives in the leadership ranks.'””
Daniel Barasa, research analyst at investment firm Gabelli Funds, said it was somewhat surprising that Pfizer chose an internal candidate for the role ‘given recent activist pressure looking for fresh perspectives in the leadership ranks.'””
